Research Nester released a report titled “Sickle Cell Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
Further,
for the in-depth analysis, the report encompasses the industry growth indicators,
restraints, supply and demand risk, along with detailed discussion on current
and future market trends that are associated with the growth of the market.
The global
sickle
cell disease drugs market is projected to record a substantial CAGR
during the forecast period, i.e., 2021-2030. By treatment type, the market is
segmented into blood transfusion, stem cell transplant, and pharmacotherapy,
out of which, the stem cell transplant segment is projected to hold the largest share in the market
during the forecast period owing to the increasing demand for stem
cell transplant, as it is the only treatment method that can completely cure
sickle cell disease. However, high cost of this treatment is expected to hamper
the segment growth. The market is segmented by
end-user into hospital, homecare, specialty clinics, and others. Out of these,
the hospital segment is projected to hold the largest market share over the
forecast period, owing to rising number of hospitals coupled with the growing
patient pool of sickle cell disease.
Download Sample of This
Strategic Report: https://www.researchnester.com/sample-request-3094
The
growth of the global sickle cell disease drugs market can be attributed to the
growing cases of the genetic disease among people on account of various factors
such as unhealthy lifestyles, and hormonal changes, among others. Due to the
deletion of chromosomes in the genes, the red blood cells get elongated and
form sickle-shape. These RBC cannot carry oxygen, which makes the affected
individual deficient in oxygen, causing various problems, such as, acute pain
in chest, swelling in limbs, and dizziness. Moreover, the increasing investment
in R&D activities, is estimated to boost the market growth.
Geographically,
the global sickle cell disease
drugs market is segmented into five major regions including North America, Europe,
Asia Pacific, Latin America and Middle East & Africa region, out of
which, the market in the North America is estimated to lead the market during
the forecast period. This can be attributed to the presence of leading
pharmaceutical companies in the region, coupled with increasing investment in
R&D activities for the development of new drugs. Moreover, increasing
government investment in healthcare sector, and high per capita healthcare
expenditure, is estimated to boost the market growth. As per the data by the
World
Health Organization (WHO), over USD 10,050.279 was spent per capita for
healthcare services in North America, in 2018. The
market in the Asia Pacific region is anticipated to hold a significant market
share over the forecast period, owing to the advanced treatment options and
high demand for targeted therapies, backed by growing population and increasing
cases of the disease.
High Medical R&D
Investments to Boost the Growth of the Market
There
is an up-surge in research related to treatment for genetic diseases, owing to
the severe symptoms of sickle cell disease. The increasing demand for novel treatment
methods, along with the growing government and private funding in the R&D
activities is estimated to boost the growth of the global sickle cell disease
drugs market over the coming years.
“The
Final Report will cover the impact analysis of COVID-19 on this industry.”
Download/Request Sample Copy of Strategic Report: https://www.researchnester.com/sample-request-3094
However, the high cost of treatment, can financially and mentally drain the patient’s family, which is anticipated to restraint the growth of the market during the forecast period.
This
report also provides the existing competitive scenario of some of the key
players of the global sickle cell disease drugs market which includes company
profiling of Addmedica SAS, Medunik USA Inc., Emmaus Life Sciences, Inc. (OTCMKTS:
EMMA), CellSeed, Inc. (TYO: 7776), Global Blood Therapeutics, Inc. (NASDAQ: GBT),
Sio Gene Therapies Ltd. (NASDAQ: SIOX), Imara, Inc. (NASDAQ: IMRA), Modus
Therapeutics AB, Bluebird bio, Inc. (NASDAQ: BLUE), and Vertex Pharmaceuticals
Incorporated (NASDAQ: VRTX). The profiling enfolds key information of the
companies which encompasses business overview, products, and services, key
financials and recent news and developments. On the whole, the report depicts a
detailed overview of the global sickle cell disease drugs market that will help industry
consultants, equipment manufacturers, existing players searching for expansion
opportunities, new players searching possibilities, and other stakeholders to
align their market-centric strategies according to the ongoing and expected
trends in the future.
More
Information@ https://www.researchnester.com/reports/sickle-cell-disease-drugs-market/3094
About Research
Nester
Research
Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market
research and consulting with an unbiased and unparalleled approach towards
helping global industrial players, conglomerates and executives for their
future investment while avoiding forthcoming uncertainties. With an
out-of-the-box mindset to produce statistical and analytical market research
reports, we provide strategic consulting so that our clients can make wise
business decisions with clarity while strategizing and planning for their
forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new
horizon, provided a right guidance at a right time is available through
strategic minds.
Contact for more
Info:
Ajay Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
No comments:
Post a Comment